Major Cancer Research Center Signs New $3.5 Million, Multiyear Commitment to OmniComm’s TrialMaster® EDC
Fort Lauderdale, FL, October 11, 2018 – With a longstanding dedication to the development of patient- centric cancer therapies, a major clinical research center has extended its commitment to TrialMaster EDC and OmniComm Systems, Inc. (OTCQX: OMCM), a leading global provider of clinical data management technology. The new multiyear transaction extends and expands an existing agreement between the two companies.
“We are delighted that OmniComm has successfully earned a renewal agreement for our TrialMaster platform with its advanced EDC and eSource technology,” said Kuno van der Post, Ph.D., chief commercial officer, OmniComm Systems. “What is significant is that this is yet another cancer research center looking to accelerate their cancer research efforts.”
The agreement will yield multiple benefits for both companies and provide the clinical research center with the opportunity to further enhance the efficiency of its clinical trials, while contributing to greater patient safety and advances in patient-centric treatments for cancer. OmniComm was selected for the partnership based on its EDC solutions, which offer inherent flexibility and broad capabilities to support clinical studies across all phases of clinical development.
Deploying studies in an efficient, timely and cost-effective manner was especially important to the research center. OmniComm’s robust, state-of-the art, compliant hosting environment was another critical factor in the selection process. With a large clinical capacity and experienced scientific staff, the research center offers one of the most experienced clinical networks in cancer research.
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry.OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract researchorganizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, these organizations drive efficiency in clinical development, better manage risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 6,000 clinical trials.
Please visit www.omnicomm.com for more information.
Trademarks
OmniComm, TrialMaster, TrialOne and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Contact Info
Kuno van der Post
OmniComm Systems, Inc.
+1.954.473.1254
kvanderpost@omnicomm.com
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.
